Key facts
- It has raised $5.7M; the latest was Angel (individual) ($5.7M) in Aug 2025.
- Notable investors include Massachusetts Institute of Technology.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Raina Biosciences
- ·The full record, as it builds
Funding rounds
No funding rounds for Raina Biosciences are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Raina Biosciences
Developer of a generative-AI-for-RNA platform designed to generate superior mRNAs with unprecedented translational capacity and stability. The company's platform integrates AI and synthetic biology technologies to design therapeutic sequences throughputs and speeds, enabling clients to accelerate drug discovery timelines and produce therapeutics for novel applications.
- Sector
- Healthcare
- HQ
- Woburn, MA, United States
- Founded
- 2023
- Website
- rainabio.com/
- Ownership
- Privately Held (backing)
Raina Biosciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Raina Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Raina Biosciences in its N-PORT filings yet. We sweep new filings monthly.